00:07 , Mar 12, 2013 |  BC Extra  |  Financial News

Alchemia raises A$10.2M in private placement

Alchemia Ltd. (ASX:ACL) raised A$10.2 million ($10.4 million) through the sale of about 34 million shares at A$0.30 in a private placement to new and existing U.S. and Australian investors. The price is a 13%...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Darwin's delight

The biotech ecosystem looks healthy moving into 2013. With the space above $1 billion more than replenished in 2012, mid-cap names have money to create their own tier-jumping stories this year, while investors see natural...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Company News

Alchemia cancer news

Alchemia delayed plans to spin out its U.S. subsidiary Audeo Oncology Inc. (San Francisco, Calif.) and list it on U.S. and Australian exchanges. The company said it was unable to secure new investments at terms...
01:33 , Dec 22, 2012 |  BC Extra  |  Financial News

Alchemia falls on listing delays for U.S. subsidiary

Alchemia Ltd. (ASX:ACL) fell A$0.15 (28%) to A$0.40 on Friday after the company delayed plans to spin out its U.S. subsidiary Audeo Oncology Inc. (San Francisco, Calif.) and list it on U.S. and Australian exchanges....
08:00 , Nov 12, 2012 |  BC Week In Review  |  Financial News

Audeo Oncology amends IPO

Audeo Oncology Inc. , San Francisco, Calif.   Business: Cancer   Date announced: 11/8/12   Type: IPO   To be raised: Up to $59.8 million   Shares: 3.3 million   Price: $14-$16   Underwriters: Leerink;...
01:54 , Nov 10, 2012 |  BC Extra  |  Financial News

Audeo sets IPO range

Audeo Oncology Inc. (San Francisco, Calif.) amended its IPO and now plans to sell 3.3 million shares at $14-$16 per share. At the mid-point of $15, Audeo would raise $48.8 million be valued at $162.6...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

4Q Financial Markets Preview: Bellwether's ball

For only the second time since 2000, the BioCentury 100 index has matched or beaten the S&P 500 for four consecutive quarters, with most of the gains driven by the bellwether names. Buysiders are cautiously...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Alchemia cancer news

Audeo Oncology Inc. , Alchemia's newly formed U.S. subsidiary, said it plans to raise up to $60 million in an IPO on NASDAQ underwritten by Leerink and Oppenheimer. Audeo also plans to undertake a secondary...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Financial News

Audeo Oncology proposes IPO

Audeo Oncology Inc. , San Francisco, Calif.   Business: Cancer   Date announced: 7/6/12   Type: IPO   To be raised: Up to $60 million   Shares: TBD   Price: TBD   Underwriters: Leerink; Oppenheimer...
01:20 , Jul 10, 2012 |  BC Extra  |  Financial News

Alchemia's oncology subsidiary proposes IPO

Audeo Oncology Inc., the newly formed U.S. subsidiary of Alchemia Ltd. (ASX:ACL), said it plans to raise up to $60 million in an IPO on NASDAQ underwritten by Leerink and Oppenheimer. The subsidiary is developing...